Search

Your search keyword '"Association of the British Pharmaceutical Industry"' showing total 631 results

Search Constraints

Start Over You searched for: Descriptor "Association of the British Pharmaceutical Industry" Remove constraint Descriptor: "Association of the British Pharmaceutical Industry"
631 results on '"Association of the British Pharmaceutical Industry"'

Search Results

1. ABPI WELCOMES THE CHANCELLOR'S BACKING OF LIFE SCIENCES IN THE BUDGET

2. LATEST COMPANY NEWS

3. Renewing the UK Voluntary Pricing Scheme: What does the 2024 VPAS mean for pharma?

4. ABPI RESPOND TO THE NEW NORTHERN IRELAND BREXIT DEAL

5. THE PRIME MINISTER CONFIRMED TODAY THAT THE NEW WINDSOR FRAMEWORK WOULD ENSURE MEDICINES APPROVED FOR USE BY THE UK REGULATOR WILL AUTOMATICALLY BECOME AVAILABLE IN NORTHERN IRELAND

6. ROUNDUP: SWISSMEDIC RESPONDS TO EU PAPER ON AVOIDING MEDICAL DEVICE SUPPLY DISRUPTIONS

7. Big pharma strikes blow to NHS patients' hopes of getting breakthrough drugs; Two major medical companies pull out of Britain's official pricing scheme at a time of soaring demand for treatment

8. Trial Decline

10. Battle with Covid pushes Britain down medical research rankings

11. ABPI NORTHERN IRELAND MANIFESTO 2022

12. Adapting Regulations Post-Brexif: The UK government is taking advantage of the new regulatory flexibility, afforded by Brexit, to boost the country's competitiveness in pharma

13. ABPI RESPONSE TO THE LATEST NICE CONSULTATION

14. SPEECH: THE FUTURE OF UK MEDICINES AND VACCINES MANUFACTURING

15. ABPI RESPONSE TO UK GOVERNMENT 100M VACCINE PLEDGE

16. ABPI STATEMENT ON INTELLECTUAL PROPERTY RIGHTS FOR COVID-19 VACCINES

17. ABPI RESPONSE TO NEW GENOMICS FUNDING

18. ABPI RESPONSE TO NEW GLOBAL PARTNERSHIP TO FIGHT FUTURE PANDEMICS

19. ABPI RESPONSE TO NICE'S 5-YEAR STRATEGY

20. ABPI RESPONSE TO NHS COMMERCIAL FRAMEWORK

21. ABPI RESPONSE TO LIFE SCIENCE COMPETITIVENESS INDICATORS

22. ABPI comment on medicine export bans

23. ABPI COMMENT ON MEDICINE EXPORT BANS

24. ABPI RESPONSE TO UK COVID-19 VACCINES DELIVERY PLAN

26. ABPI RESPONSE TO THE SPENDING REVIEW

27. ABPI RESPONSE TO CONSULTATION ON NICE'S METHODS

28. A GLOBAL SCIENCE SUPERPOWER: THE FUTURE OF MEDICINES VALUATION

29. ABPI RESPONSE TO PM'S BREXIT COMMENTS

30. UK leads Europe in Phase I and Phase II trials, ABPI findings show

31. ABPI RESPONSE TO GOVERNMENT-SECURED BREXIT FREIGHT CAPACITY

32. ABPI calls on UK government to create non-COVID clinical research strategy

33. THE TASKFORCE FOR LUNG HEALTH SHOWS THAT COLLABORATION GETS RESULTS

34. ABPI RESPONSE TO NHS CONFEDERATION REPORTS: NHS RESET AND HEALTH INEQUALITIES

35. MHRA publishes guidance on medicine regulation after Brexit

36. ABPI RESPONSE TO MHRA GUIDANCE FOR THE END OF THE TRANSITION PERIOD

37. $1 BILLION ANTIBIOTICS RESEARCH FUND LAUNCHED BY PHARMACEUTICAL COMPANIES

38. Payments from UK pharma to healthcare professionals increased in 2019

40. ABPI CONSULTS ON NEW-LOOK CODE OF PRACTICE

41. PUBLIC-PRIVATE ALLIANCE TO PROVIDE IMMUNISATION PROGRAMS FOR 300 MILLION CHILDREN GLOBALLY

42. GAVI: PARTNERING TO PROTECT FUTURE GENERATIONS FROM INFECTIOUS DISEASES

43. ABPI RESPONDS TO GOVERNMENT'S CORONAVIRUS TESTING 'CALL TO ARMS'

44. ABPI UPDATE ON THE PHARMACEUTICAL INDUSTRY'S RESPONSE TO CORONAVIRUS

45. PHARMACEUTICAL INDUSTRY RESPONSE TO BUDGET 2020

46. ABPI RESPONSE TO UK NEGOTIATING OBJECTIVES FOR US FTA

47. ABPI RESPONSE TO THE UK'S APPROACH TO EU NEGOTIATIONS

48. NOVARTIS HAS ANNOUNCED A COLLABORATION WITH NHS ENGLAND, THE NATIONAL INSTITUTE FOR HEALTH RESEARCH AND OXFORD UNIVERSITY

50. ANALYSIS: WHAT DOES THE CONSERVATIVE GENERAL ELECTION MANIFESTO MEAN FOR US?

Catalog

Books, media, physical & digital resources